Tenofovir disoproxil fumarate associated nephrotoxicity : a retrospective cohort study at two referral hospitals in Namibia

Kalemeera, Francis and Godman, Brian and Stergachis, Andy and Rennie, Tim (2020) Tenofovir disoproxil fumarate associated nephrotoxicity : a retrospective cohort study at two referral hospitals in Namibia. Pharmacoepidemiology and Drug Safety. ISSN 1053-8569

Text (Kalameera-etal-PDS-2020-Tenofovir-disoproxil-fumarate-associated-nephrotoxicity-a-retrospective-cohort) Kalameera_etal_PDS_2020_Tenofovir_disoproxil_fumarate_associated_nephrotoxicity_a_retrospective_cohort.pdf Accepted Author Manuscript Restricted to Repository staff only until 2 October 2021. Download (1MB) | Request a copy from the Strathclyde author

Abstract

Introduction: The incidence and risk factors of tenofovir disoproxil fumarate (TDF)-related renal impairment (RI) in Namibia are unknown where TDF-containing ART regimens are used as the first line for HIV. Methodology: A retrospective cohort study among HIV-infected patients at two intermediate hospitals. A decline in estimated glomerular filtration rate (eGFR) was significant if it was ≥25% and included a change to a lower eGFR stage. New-onset RI was defined as an eGFR <50 mL/min/1.73m 2. Results: 10 387 patients were included: 11.4% (n = 1182) experienced the decline in eGFR. Of these, 0.6% (n = 62) migrated to eGFR stages IV and V. The incidence was 4.5 (95% CI: 4.3-4.8) per 100 patient years. RI developed in 400 patients for an incidence rate of 2.4 (95% CI: 2.2-2.6) cases per 100 patient years. Risk factors with effect sizes >2.0, for decline-in-eGFR were baseline eGFR >60 (aHR = 15.6); hyperfiltration (aHR = 5.0); and pregnancy (aHR = 2.4); while for RI, they were hyperfiltration (aHR = 4.1) and pregnancy (aHR = 29). Conclusion: The incidence of decline-in-eGFR was higher than in other sub-SSA countries, but not RI. A high baseline eGFR had the greatest risk for the decline, and hyperfiltration for the RI.